VYNDAMAX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VYNDAMAX (VYNDAMAX).
Tafamidis binds to transthyretin (TTR), stabilizing the tetrameric form and inhibiting dissociation into monomers, which are prone to amyloid fibril formation. This prevents amyloid deposition in tissues.
| Metabolism | Primarily metabolized by glucuronidation via UGT1A1, UGT1A3, and UGT1A9; minor CYP3A4 involvement. |
| Excretion | Primarily excreted unchanged in feces (87% of administered dose) via biliary secretion; renal excretion is minimal (<1% unchanged in urine). |
| Half-life | Terminal elimination half-life is approximately 50 hours, supporting once-daily dosing and achieving steady state within 2 weeks. |
| Protein binding | Highly bound to plasma proteins, predominantly albumin (99.7% bound). |
| Volume of Distribution | Apparent volume of distribution is approximately 18 L (0.2-0.3 L/kg), indicating limited distribution into tissues. |
| Bioavailability | Absolute oral bioavailability is approximately 60-70% under fasting conditions; absorption is reduced by high-fat meals. |
| Onset of Action | Oral: Clinical effect onset is gradual; reduction in transthyretin stabilization occurs within days, but symptomatic benefit may take weeks to months. |
| Duration of Action | Duration of action is sustained with daily dosing due to long half-life; continuous stabilization of TTR tetramers is maintained throughout the dosing interval. |
61 mg orally once daily.
| Dosage form | CAPSULE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (CrCl <30 mL/min) or dialysis; use with caution. |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate to severe hepatic impairment (Child-Pugh B or C). |
| Pediatric use | Not indicated in pediatric patients; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; geriatric patients (≥65 years) have been included in clinical trials with similar safety and efficacy as younger adults. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VYNDAMAX (VYNDAMAX).
| Breastfeeding | There are no data on the presence of tafamidis in human milk, the effects on the breastfed infant, or the effects on milk production. Tafamidis is excreted in the milk of lactating rats. When a drug is present in animal milk, it is likely to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for tafamidis and any potential adverse effects on the breastfed infant from tafamidis or from the underlying maternal condition. The milk-to-plasma (M/P) ratio in rats is approximately 0.98, but this is not directly translatable to humans. |
| Teratogenic Risk | There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, tafamidis administration to pregnant rabbits during organogenesis resulted in developmental toxicity, including increased embryofetal mortality and decreased fetal body weight, at doses producing maternal exposures approximately 39 times the human exposure at the recommended human dose of 61 mg. Based on its mechanism of action, tafamidis may cause fetal harm when administered to a pregnant woman. Tafamidis is a transthyretin stabilizer; transthyretin is involved in thyroxine transport. Disruption of maternal thyroxine levels during pregnancy may affect fetal neurodevelopment. Therefore, tafamidis should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. There is no information on the risk of miscarriage or malformations in humans. |
■ FDA Black Box Warning
None.
| Serious Effects |
["None known."]
| Precautions | ["Not recommended for use in patients with NYHA Class IV heart failure due to lack of efficacy data.","Monitor for hepatotoxicity; liver function tests should be performed periodically.","Risk of volume depletion; ensure adequate hydration."] |
Loading safety data…
| Fetal Monitoring | Monitor pregnant women exposed to tafamidis for signs of fetal distress, including assessment of fetal growth and well-being via ultrasound, amniotic fluid volume, and non-stress testing as clinically indicated. Monitor maternal thyroid function (TSH, free T4) regularly throughout pregnancy, as tafamidis may alter thyroid hormone levels due to thyroxine displacement from transthyretin. Assess for symptoms of hypothyroidism and adjust levothyroxine dose if needed. Monitor liver function tests (ALT, AST, bilirubin) and renal function (serum creatinine, BUN) periodically due to potential for hepatic and renal impairment. In infants, monitor for signs of hypothyroidism and neurodevelopmental outcomes. |
| Fertility Effects | Based on animal studies, tafamidis may impair male fertility. In male rats, tafamidis administration resulted in reduced fertility and sperm count at exposures approximately 21 times the human exposure. No significant effects on female fertility were observed in animal studies. There are no human data on fertility effects. It is unknown whether tafamidis affects human fertility. |